REPRONEX
LOE ApproachingBLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REPRONEX is a gonadotropin injectable used in assisted reproductive technology (ART) to stimulate follicle development in women undergoing fertility treatment. The exact mechanism involves recombinant FSH activity delivered via intramuscular or subcutaneous injection. It is indicated for ovulation induction in patients with infertility.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect defensive positioning and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REPRONEX is a mature, specialty fertility injectable with minimal open positions and declining career opportunity as the product approaches LOE. Professionals joining this team should expect focus on managed care negotiations, provider relationships, and competitive defense rather than growth initiatives.
Brand ManagerMedical Science Liaison
Worked on REPRONEX at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.